Details
Title
Extreme body mass index and survival in newly diagnosed multiple myeloma patients
Author
Shah, Urvi A. 1
; Whiting, Karissa 2 ; Devlin, Sean 2 ; Ershler, Rachel 3 ; Kanapuru, Bindu 3 ; Lee, David J. 4 ; Tahri, Sabrin 5 ; Gwise, Thomas 6 ; Rustad, Even H. 7 ; Mailankody, Sham 1
; Lesokhin, Alexander M. 1 ; Kazandjian, Dickran 8 ; Maura, Francesco 8
; Auclair, Daniel 9 ; Birmann, Brenda M. 10
; Usmani, Saad Z. 1 ; Gormley, Nicole 3 ; Marinac, Catherine R. 11
; Landgren, Ola 8
1 Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952); Weill Cornell Medical College, Department of Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
2 Memorial Sloan Kettering Cancer Center, New York, Department of Epidemiology and Biostatistics, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
3 Center for Drug Evaluation and Research, U.S. Food, and Drug Administration, Division of Hematologic Malignancies II, Beltsville, USA (GRID:grid.483500.a) (ISNI:0000 0001 2154 2448)
4 Massachusetts General Hospital, Department of Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
5 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Erasmus University Medical Center, Department of Hematology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
6 U.S. Food and Drug Administration, Division of Biometrics IX, Center for Drug Evaluation and Research, Beltsville, USA (GRID:grid.417587.8) (ISNI:0000 0001 2243 3366)
7 Oslo University Hospital Radiumhospitalet, Department of Cancer Immunology, Institute for Cancer Research, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485); Lovisenberg Diaconal Hospital, Department of Medicine, Oslo, Norway (GRID:grid.416137.6) (ISNI:0000 0004 0627 3157)
8 Sylvester Comprehensive Cancer Center at the University of Miami, Department of Medicine, Miami, USA (GRID:grid.419791.3) (ISNI:0000 0000 9902 6374)
9 Multiple Myeloma Research Foundation, Norwalk, USA (GRID:grid.429426.f) (ISNI:0000 0000 9350 5788)
10 Brigham and Women’s Hospital and Harvard Medical School, Channing Division of Network Medicine, Department of Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
11 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
; Whiting, Karissa 2 ; Devlin, Sean 2 ; Ershler, Rachel 3 ; Kanapuru, Bindu 3 ; Lee, David J. 4 ; Tahri, Sabrin 5 ; Gwise, Thomas 6 ; Rustad, Even H. 7 ; Mailankody, Sham 1
; Lesokhin, Alexander M. 1 ; Kazandjian, Dickran 8 ; Maura, Francesco 8
; Auclair, Daniel 9 ; Birmann, Brenda M. 10
; Usmani, Saad Z. 1 ; Gormley, Nicole 3 ; Marinac, Catherine R. 11
; Landgren, Ola 8
1 Memorial Sloan Kettering Cancer Center, Myeloma Service, Department of Medicine, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952); Weill Cornell Medical College, Department of Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
2 Memorial Sloan Kettering Cancer Center, New York, Department of Epidemiology and Biostatistics, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
3 Center for Drug Evaluation and Research, U.S. Food, and Drug Administration, Division of Hematologic Malignancies II, Beltsville, USA (GRID:grid.483500.a) (ISNI:0000 0001 2154 2448)
4 Massachusetts General Hospital, Department of Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
5 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Erasmus University Medical Center, Department of Hematology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
6 U.S. Food and Drug Administration, Division of Biometrics IX, Center for Drug Evaluation and Research, Beltsville, USA (GRID:grid.417587.8) (ISNI:0000 0001 2243 3366)
7 Oslo University Hospital Radiumhospitalet, Department of Cancer Immunology, Institute for Cancer Research, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485); Lovisenberg Diaconal Hospital, Department of Medicine, Oslo, Norway (GRID:grid.416137.6) (ISNI:0000 0004 0627 3157)
8 Sylvester Comprehensive Cancer Center at the University of Miami, Department of Medicine, Miami, USA (GRID:grid.419791.3) (ISNI:0000 0000 9902 6374)
9 Multiple Myeloma Research Foundation, Norwalk, USA (GRID:grid.429426.f) (ISNI:0000 0000 9350 5788)
10 Brigham and Women’s Hospital and Harvard Medical School, Channing Division of Network Medicine, Department of Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
11 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
Pages
13
Publication year
2023
Publication date
Dec 2023
e-ISSN
20445385
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2764016812
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.